Everolimus- Versus Biolimus-Eluting Stents in All-Comers (EverBio)
This study sought to investigate safety and efficacy of biolimus-eluting stents (BES) with biodegradable polymer as compared with everolimus-eluting stents (EES) with durable polymer through 3 years of follow-up.
Percutaneous Coronary Intervention
|Study Design:||Observational Model: Cohort
Time Perspective: Prospective
|Official Title:||Long-Term Comparison of Everolimus-Eluting and Biolimus-Eluting Stents in All-Comer Patients|
- Composite of Death, Myocardial Infarction and Target Vessel Revascularization [ Time Frame: up to 24 months ] [ Designated as safety issue: Yes ]The primary outcome is the above mentioned composite of adverse events in order to measure their cumulative incidence (i.e. the rate of occurrence of such events in the study population over a predefined time periode).
- Cardiovascular death [ Time Frame: up to 24 months ] [ Designated as safety issue: Yes ]
- Any Revascularization [ Time Frame: up to 24 months ] [ Designated as safety issue: Yes ]
|Study Start Date:||November 2010|
|Study Completion Date:||November 2011|
|Primary Completion Date:||November 2010 (Final data collection date for primary outcome measure)|
everolimus-eluting stents (EES)
Second-generation everolimus-eluting stents (EES) have been shown to be superior to the first-generation paclitaxel eluting stents (PES) in terms of safety and efficacy.
biolimus-eluting stents (BES)
Third generation biolimus-eluting stents (BES) have been shown to be superior to the PES and non inferior to first-generation sirolimus eluting stents in terms of safety and efficacy.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01472705
|Cardiology, university Fribourg Medical Center|
|Fribourg, Switzerland, 1708|
|Study Chair:||Stéphane P Cook, MD||University Fribourg|
|Study Director:||Mario Togni, MD||University Fribourg|
|Principal Investigator:||Markus Oberhänsli, MD||University Fribourg|